You are browsing the Hong Kong website, Regulated by Hong Kong SFC (CE number: BJA907). Investment is risky and you must be cautious when entering the market.
格隆匯港股聚焦(9.03)︱中國恆大前8月合約銷售4506億元;信達生物阿達木單抗正式獲批上市
格隆匯 09-03 23:14

【運營數據】

中國恆大(03333.HK)前8月合約銷售4506.2億元 同比增長21.8%

融信中國(03301.HK)8月總合約銷售額120.31億元 同比增長10.09%

越秀地產(00123.HK)8月合同銷售76.57億元 同比上升約132%

雅居樂集團(03383.HK):8月預售金額119.6億元 同比增長17.8%

銀城國際控股(01902.HK)8月份合約銷售同比增長86.97%

首創置業(02868.HK):8月簽約額38.5億元 同比增長30.5%

德信中國(02019.HK)8月合約銷售額67.4億元 同比增長81.18%

大發地產(06111.HK)前8個月銷售額達160.02億元

捷利交易寶(08017.HK)8月註冊用户量同比增長58.2%

【增減持】

香港建設(控股)(00190.HK)斥1.25億港元收購604萬股小米集團(01810.HK)股份

青島啤酒股份(00168.HK):復星集團減持公司3600萬股H股

睿見教育(06068.HK)控股股東劉學斌再次增持100萬股

【股權變更】

山東國信(01697.HK):山東高新投擬將所持公司4.83%股權轉讓予魯信集團

【股本重組】

艾碩控股(08341.HK)擬“1供3”供股 籌集最多4800萬港元

【併購出售】

正乾金融控股(01152.HK)擬85萬元收購深圳綜合跨境電商平台

【重大事項】

創維集團(00751.HK)股份回購要約截止 黃氏一致行動集團持股將增至46.90%

勵晶太平洋(00575.HK):Fortacin營銷授權由處方藥轉為非處方藥以大幅提升銷量

李氏大藥廠(00950.HK)抗精神病吸入劑產品研究達到主要終點指標

信達生物(01801.HK):蘇立信®(阿達木單抗生物類似藥)獲批上市

康寧傑瑞製藥-B(09966.HK)治療胸腺上皮腫瘤新藥獲孤兒藥資格認定

中國同輻(01763.HK)附屬與韓國FC於放射性FC303藥物開發和商業化進行合作

【公司改名】

中糧肉食(01610.HK)擬更名為“中糧家佳康食品”

【回購註銷】

中國旺旺(00151.HK)9月3日耗資5945.46萬港元回購1100萬股

合生創展集團(00754.HK)9月3日耗資1498.59萬港元回購95萬股

復星國際(00656.HK)9月3日耗資1722.8萬港元回購200萬股

石四藥集團(02005.HK)9月3日耗資390.1萬港元回購80萬股

數碼通電訊(00315.HK)9月3日耗資525.52萬港元回購125萬股

富智康集團(02038.HK)9月3日耗資182萬港元回購200萬股

金鷹商貿集團(03308.HK)9月3日耗資327.91萬港元回購45.5萬股

昊海生物科技(06826.HK)9月3日耗資101.06萬港元回購1.77萬股H股

DYNAM JAPAN(06889.HK)9月3日耗資307.35萬港元回購38.94萬股

康臣藥業(01681.HK)9月3日耗資117.30萬港元回購35.6萬股

中國水務(00855.HK)9月3日耗資139.6萬港元回購22.2萬股

【股權激勵】

高豐集團控股(02863.HK)授出4326萬份購股權

金寶通(00320.HK)向執行董事黃華舜授出200萬份購股權

Follow us
Find us on Facebook, Twitter , Instagram, and YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!
Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.
uSMART
Wealth Growth Made Easy
Open Account